On November 23, 2021 Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, reported that it will take part in a fireside chat at the Evercore ISI HealthCONx Conference, which will be webcast on December 2 at 11:15 a.m. P.T. / 2:15 p.m. E.T. David Meek, chief executive officer and Charles Baum, M.D., Ph.D., president, founder and head of research and development, will represent the company (Press release, Mirati, NOV 23, 2021, https://www.prnewswire.com/news-releases/mirati-therapeutics-to-participate-in-the-4th-annual-evercore-isi-healthconx-conference-301430391.html [SID1234595996]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The webcast will be available through the "Investors and Media" section on Mirati.com and a replay of the webcast will be made available following the event.